← Human Trials & Peer-Reviewed Studies
Vitamin D and hyperparathyroidism in obesity.
Plain-language guide to PMID 21325456 (2011): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 48 women, hyperparathyroidism.
Key Facts
- PMID
- 21325456
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Grethen E et al. (10 authors)
- DOI
- 10.1210/jc.2010-2202
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism.
Their aims were to determine in obesity whether there was vitamin D insufficiency, assessed by serum 25-hydroxyvitamin D (s25D) and serum PTH (sPTH) and whether it related to comorbid conditions.
Why It Was Studied
Low vitamin D status and hyperparathyroidism occur in obesity and may be involved in pathogenesis of obesity-associated comorbid conditions.
Who Took Part
According to the abstract, 48 women were involved.
By PubMed's age tags, the people studied were adults and middle-aged adults, women only.
The researchers conducted a case-control study of 48 women having bariatric surgery and 50 healthy women frequency matched for race, age, year, and season of study.
Height, weight, s25D, sPTH, serum 1,25-dihydroxyvitamin D (s1,25D), serum bone alkaline phosphatase, serum cross-linked N-telopeptides of type 1 collagen, and serum calcium, phosphate, creatinine, glucose, and insulin were measured, and comorbid conditions were documented from patient files.
How the Study Was Run
The design is described as randomized.
Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.
What Was Measured
PubMed files the paper under topics including Age Factors, Anastomosis, Roux-en-Y, Anthropometry, Case-Control Studies, Data Interpretation, Statistical, Dihydroxycholecalciferols and Hyperparathyroidism.
What This Means in Plain Language
The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 48 women in people with hyperparathyroidism.
Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.